You just read:

SELLAS Life Sciences Reports Promising Top-Line Phase 2 Data for WT1 Vaccine in Mesothelioma and Acute Myeloid Leukemia (AML) Patients

News provided by

SELLAS Life Sciences Group

Oct 12, 2015, 12:14 ET